Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Drug Law Gets Pfizer Support; More Exclusivity “Trades-Off” With Generics

Executive Summary

Pfizer CEO Hank McKinnell supports European drug regulation legislation that provides extended marketing exclusivity and speeds the entry of generics

You may also be interested in...



Pediatric Exclusivity Incentives Proposed In European Commission Draft Reg

A draft European Commission regulation would create a new "Pediatric Use Marketing Authorization" to encourage the study of off-patent drugs in children

Pediatric Exclusivity Incentives Proposed In European Commission Draft Reg

A draft European Commission regulation would create a new "Pediatric Use Marketing Authorization" to encourage the study of off-patent drugs in children

Pfizer “Evolves” From Rx To Health Care Company: Fla. Medicaid Is Blueprint

Pfizer plans to follow the blueprint set by its disease management agreement in Florida to forge "creative" agreements with other public and private payors, CFO David Shedlarz told the J.P. Morgan health care conference in San Francisco Jan. 14

Related Content

UsernamePublicRestriction

Register

PS043201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel